The role of BRAF V600 mutation in melanoma
<p>Abstract</p> <p>BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which...
| मुख्य लेखकों: | , , , , , , , , , |
|---|---|
| स्वरूप: | लेख |
| भाषा: | English |
| प्रकाशित: |
BMC
2012-07-01
|
| श्रृंखला: | Journal of Translational Medicine |
| विषय: | |
| ऑनलाइन पहुंच: | http://www.translational-medicine.com/content/10/1/85 |
| _version_ | 1831611145647030272 |
|---|---|
| author | Ascierto Paolo A Kirkwood John M Grob Jean-Jacques Simeone Ester Grimaldi Antonio M Maio Michele Palmieri Giuseppe Testori Alessandro Marincola Francesco M Mozzillo Nicola |
| author_facet | Ascierto Paolo A Kirkwood John M Grob Jean-Jacques Simeone Ester Grimaldi Antonio M Maio Michele Palmieri Giuseppe Testori Alessandro Marincola Francesco M Mozzillo Nicola |
| author_sort | Ascierto Paolo A |
| collection | DOAJ |
| description | <p>Abstract</p> <p>BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.</p> |
| first_indexed | 2024-12-18T18:26:43Z |
| format | Article |
| id | doaj.art-e34aa8e10db24e9dba9f6feb4558168b |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-18T18:26:43Z |
| publishDate | 2012-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-e34aa8e10db24e9dba9f6feb4558168b2022-12-21T20:57:34ZengBMCJournal of Translational Medicine1479-58762012-07-011018510.1186/1479-5876-10-85The role of BRAF V600 mutation in melanomaAscierto Paolo AKirkwood John MGrob Jean-JacquesSimeone EsterGrimaldi Antonio MMaio MichelePalmieri GiuseppeTestori AlessandroMarincola Francesco MMozzillo Nicola<p>Abstract</p> <p>BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.</p>http://www.translational-medicine.com/content/10/1/85BRAFVemurafenibMelanoma |
| spellingShingle | Ascierto Paolo A Kirkwood John M Grob Jean-Jacques Simeone Ester Grimaldi Antonio M Maio Michele Palmieri Giuseppe Testori Alessandro Marincola Francesco M Mozzillo Nicola The role of BRAF V600 mutation in melanoma Journal of Translational Medicine BRAF Vemurafenib Melanoma |
| title | The role of BRAF V600 mutation in melanoma |
| title_full | The role of BRAF V600 mutation in melanoma |
| title_fullStr | The role of BRAF V600 mutation in melanoma |
| title_full_unstemmed | The role of BRAF V600 mutation in melanoma |
| title_short | The role of BRAF V600 mutation in melanoma |
| title_sort | role of braf v600 mutation in melanoma |
| topic | BRAF Vemurafenib Melanoma |
| url | http://www.translational-medicine.com/content/10/1/85 |
| work_keys_str_mv | AT asciertopaoloa theroleofbrafv600mutationinmelanoma AT kirkwoodjohnm theroleofbrafv600mutationinmelanoma AT grobjeanjacques theroleofbrafv600mutationinmelanoma AT simeoneester theroleofbrafv600mutationinmelanoma AT grimaldiantoniom theroleofbrafv600mutationinmelanoma AT maiomichele theroleofbrafv600mutationinmelanoma AT palmierigiuseppe theroleofbrafv600mutationinmelanoma AT testorialessandro theroleofbrafv600mutationinmelanoma AT marincolafrancescom theroleofbrafv600mutationinmelanoma AT mozzillonicola theroleofbrafv600mutationinmelanoma AT asciertopaoloa roleofbrafv600mutationinmelanoma AT kirkwoodjohnm roleofbrafv600mutationinmelanoma AT grobjeanjacques roleofbrafv600mutationinmelanoma AT simeoneester roleofbrafv600mutationinmelanoma AT grimaldiantoniom roleofbrafv600mutationinmelanoma AT maiomichele roleofbrafv600mutationinmelanoma AT palmierigiuseppe roleofbrafv600mutationinmelanoma AT testorialessandro roleofbrafv600mutationinmelanoma AT marincolafrancescom roleofbrafv600mutationinmelanoma AT mozzillonicola roleofbrafv600mutationinmelanoma |